

DAFTAR PUSTAKA

1. Pugliese G. Updating the natural history of diabetic nephropathy. *Acta Diabetol.* 2014;51(6):905–15.
2. Wan Q, Xu Y, Dong E. Diabetic nephropathy research in China: Data analysis and review from the National Natural Science Foundation of China. *J Diabetes.* 2015;7(3):307–14.
3. Kementerian Kesehatan Republik Indonesia [Internet]. Laporan nasional RISKESDAS 2018; 2018. Available from: <http://labdata.litbang.kemkes.go.id/ccount/click.php?id=19>
4. Motta LA, Shephard MDS, Brink J, Lawson S, Rheeder P. Point-of-care testing improves diabetes management in a primary care clinic in South Africa. *Prim Care Diabetes.* 2017;11(3):248–53.
5. Dahiru T, Jibo A, Hassan AA, Mande AT. Prevalence of diabetes in a semi-urban community in Northern Nigeria. *Niger J Med.* 2008;17(4):414–6.
6. ES HS, Decroli E, Afriwardi A. Faktor Risiko Pasien Nefropati Diabetik Yang Dirawat Di Bagian Penyakit Dalam Rsup Dr. M. Djamil Padang. *J Kesehat Andalas.* 2018;7(2):149.
7. Van Buren PN, Toto R. Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management. *Adv Chronic Kidney Dis* [Internet]. 2011;18(1):28–41. Available from: <http://dx.doi.org/10.1053/j.ackd.2010.10.003>
8. Liu N, Wang Y. Association between angiotensinogen T174M polymorphism and the risk of diabetic nephropathy: A meta-analysis. *JRAAS - J Renin-Angiotensin-Aldosterone Syst.* 2019;20(1).
9. Makuc J, Šeruga M, Završnik M, Cilenšek I, Petrovič D. Angiotensinogen (AGT) gene missense polymorphisms (rs699 and rs4762) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus. *Bosn J Basic Med Sci.* 2017;17(3):262–7.
10. Rahimi Z. The Role of Renin Angiotensin Aldosterone System Genes in

Diabetic Nephropathy. *Can J Diabetes* [Internet]. 2016;40(2):178–83.

Available from: <http://dx.doi.org/10.1016/j.jcjd.2015.08.016>

11. El-garawani IM, Shaheen EM, El-seedi HR, Khalifa SMA, Mersal GAM, Emara MM, et al. Angiotensinogen gene missense polymorphisms (Rs699 and rs4762): The association of end-stage renal failure risk with type 2 diabetes and hypertension in egyptians. *Genes (Basel)*. 2021;12(3):1–11.
12. Tziastoudi M, Stefanidis I, Zintzaras E. The genetic map of diabetic nephropathy: Evidence from a systematic review and meta-analysis of genetic association studies. *Clin Kidney J*. 2020;13(5):768–81.
13. Amelia R, Burhan B, Lelo A. The relationship between anthropometry and ankle-brachial index with blood glucose level in patients with type 2 diabetes mellitus at the community health center in Medan, Indonesia. *Fam Med Prim Care Rev*. 2018;20(4):307–12.
14. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: A position statement by the American diabetes association. *Diabetes Care*. 2017;40(1):136–54.
15. Made Yogi Krisnanda MRS. HUBUNGAN STATUS NUTRISI BERDASARKAN SUBJECTIVE GLOBAL ASSESSMENT (SGA) DAN PATIENT GENERATED SUBJECTIVE GLOBAL ASSESSMENT (PG-SGA) TERHADAP KONTROL GULA DARAH PADA PASIEN DIABETIK NEFROPATI. *E-JURNAL Med*. 2017;6:6.
16. Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. *Am J Kidney Dis*. 2018;71(6):884–95.
17. Lawes CMM, Hoorn S Vander, Law MR, Elliott P, Macmahon S, Rodgers A. High blood pressure- World Health Organization. 2000;281–389.
Available from:
<https://www.who.int/publications/cra/chapters/volume1/0281-0390.pdf>
18. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015 [Internet]. Perkeni. 2015. 78 p. Available from:
<http://pbperkeni.or.id/doc/konsensus.pdf>

19. Perhimpunan Dokter Hipertensi Indonesia. Konsensus Hipertensi. 2019;118. Available from:
http://www.inash.or.id/upload/event/event_Update_konsensus_2019123191.pdf
20. Patel DM, Bose M, Cooper ME. Glucose and blood pressure-dependent pathways—the progression of diabetic kidney disease. *Int J Mol Sci.* 2020;21(6).
21. Griffin TP, Wall D, Browne GA, Dennedy MC, O'Shea PM. Associations between glycaemic control and activation of the renin-angiotensin-aldosterone system in participants with type 2 diabetes mellitus and hypertension. *Ann Clin Biochem.* 2018;55(3):373–84.
22. Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. *J Vet Intern Med.* 2019;33(2):363–82.
23. Rahayu P. ANALISIS VARIASI GENETIK *Amnirana nicobariensis* (Stoliczka, 1870)(ANURA: RANIDAE) DI SUMATERA BARAT BERDASARKAN SITOKROM OKSIDASE SUBUNIT 1 (CO1). Universitas Andalas; 2018.
24. Zhou B, Wen M, Mi L, Hu CJ, Zhang Y, Wang JT, et al. Associations between angiotensinogen M235T polymorphisms and the risk of diabetic nephropathy: A meta-analysis. *Diabetes Res Clin Pract.* 2018;142:26–36.
25. Yako YY, Balti E V., Matsha TE, Dzudie A, Kruger D, Sobngwi E, et al. Genetic factors contributing to hypertension in African-based populations: A systematic review and meta-analysis. *J Clin Hypertens.* 2018;20(3):485–95.
26. Khatami M, Heidari MM, Hadadzadeh M, Scheiber-Mojdehkar B, Sani MB, Houshmand M. Simultaneous genotyping of the Rs4762 and Rs699 polymorphisms in angiotensinogen gene and correlation with iranian cad patients with novel hexa-primer ARMS-PCR. *Iran J Public Health.* 2017;46(6):811–9.
27. Almeida lucas F. No Title. Role renin-angiotensin Syst kidney Dev Program pf adult blood Press [Internet]. 2020; Available from:

<https://doi.org/10.1042/CS20190765%0A>

28. Kurniawaty BE. jurnal international 3 upld.docx. 2020;
29. Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. *Diabetes, Obes Metab.* 2020;22(S1):3–15.
30. Drawz P, Ghazi L. Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy. *F1000Research.* 2017;6(0):1–10.
31. Ramalingam L, Menikdiwela K, LeMieux M, Dufour JM, Kaur G, Kalupahana N, et al. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. *Biochim Biophys Acta - Mol Basis Dis* [Internet]. 2017;1863(5):1106–14. Available from: <http://dx.doi.org/10.1016/j.bbadis.2016.07.019>
32. Elfiani E, Halim R, Hakir MH. Hubungan Antara Kadar Tgf-B1 Dengan Kadar Albumin Dalam Urin Pasien Dm Tipe-2 Dengan Nefropati Diabetik. *JAMBI Med J “Jurnal Kedokt dan Kesehatan.”* 2019;7(1):73–81.
33. Elfiani E, Nasrul E, Yanwirasti Y, Ali Z, Puspasari A. Plasma levels of the engulfment and cell motility protein-1 are associated with kidney damage in diabetic nephropathy: A single-center pilot study in Indonesia population. *Open Access Maced J Med Sci.* 2020;8(A):418–22.
34. SNPPedia rs699 [Internet]. Available from: <https://www.snppedia.com/index.php/rs699>
35. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. *Clin J Am Soc Nephrol.* 2017;12(12):2032–45.
36. Care D, Suppl SS. Microvascular complications and foot care: Standards of medical care in Diabetesd2018. *Diabetes Care.* 2018;41(January):S105–18.
37. Maqbool M, Cooper ME, Jandeleit-Dahm KAM. Cardiovascular Disease and Diabetic Kidney Disease. *Semin Nephrol* [Internet]. 2018;38(3):217–32. Available from: <http://dx.doi.org/10.1016/j.semnephrol.2018.02.003>
38. Kusdiyah E, Makmur MJ, Berlian R, Aras P. Karakteristik Faktor-Faktor

Risiko Terjadinya Komplikasi Kronik Nefropati Diabetik Dan Atau Penyakit Pembuluh Darah Perifer Pada Penderita Diabetes Melitus Di RSUD Raden Mattaher Tahun 2018. e-SEHAD. 2018;1(1):19–32.

39. Decroli E. Diabetes mellitus tipe 2. Kam A, Rahmadi A, Dacroli G, Effendi yandi, editors. padang; 2019.
40. Seidu S, Barrat J, Khunti K. Clinical update: The important role of dual kidney function testing (ACR and eGFR) in primary care: Identification of risk and management in type 2 diabetes. Prim Care Diabetes [Internet]. 2020;14(4):370–5. Available from: <https://doi.org/10.1016/j.pcd.2020.02.006>
41. Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol [Internet]. 2018;14(6):361–77. Available from: <http://dx.doi.org/10.1038/s41581-018-0001-y>
42. Podgórski P, Konieczny A, Lis Ł, Witkiewicz W, Hraby Z. Glomerular podocytes in diabetic renal disease. Adv Clin Exp Med. 2019;28(12):1711–5.
43. Pasala S, Carmody JB. How to use... serum creatinine, cystatin C and GFR. Arch Dis Child Educ Pract Ed. 2017;102(1):37–43.
44. Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus complications review-article. Hypertens Res [Internet]. 2018;41(3):147–56. Available from: <http://dx.doi.org/10.1038/s41440-017-0008-y>
45. Ohishi M. Hypertension with diabetes mellitus: Physiology and pathology review-article. Hypertens Res. 2018;41(6):389–93.
46. Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Bhansali A, Sud K, et al. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol. 2009;28(3):141–50.